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Abstract
Background: Japanese encephalitis virus (JEV) infection is a major cause of acute encephalopathy in children,
which destroys central nervous system (CNS) cells, including astrocytes and neurons. Matrix metalloproteinase
(MMP)-9 has been shown to degrade components of the basal lamina, leading to disruption of the blood-brain
barrier (BBB) and to contribute to neuroinflammatory responses in many neurological diseases. However, the
detailed mechanisms of JEV-induced MMP-9 expression in rat brain astrocytes (RBA-1 cells) are largely unclear.
Methods: In this study, the effect of JEV on expression of MMP-9 was determined by gelatin zymography, western
blot analysis, RT-PCR, and promoter assay. The involvement of AP-1 (c-Jun and c-Fos), c-Src, PDGFR, PI3K/Akt, and
MAPKs in these responses were investigated by using the selective pharmacological inhibitors and transfection
with siRNAs.
Results: Here, we demonstrate that JEV induces expression of pro-form MMP-9 via ROS/c-Src/PDGFR/PI3K/Akt/
MAPKs-dependent, AP-1 activation in RBA-1 cells. JEV-induced MMP-9 expression and promoter activity were
inhibited by pretreatment with inhibitors of AP-1 (tanshinone), c-Src (PP1), PDGFR (AG1296), and PI3K (LY294002),
and by transfection with siRNAs of c-Jun, c-Fos, PDGFR, and Akt. Moreover, JEV-stimulated AP-1 activation was
inhibited by pretreatment with the inhibitors of c-Src, PDGFR, PI3K, and MAPKs.
Conclusion: From these results, we conclude that JEV activates the ROS/c-Src/PDGFR/PI3K/Akt/MAPKs pathway,
which in turn triggers AP-1 activation and ultimately induces MMP-9 expression in RBA-1 cells. These findings
concerning JEV-induced MMP-9 expression in RBA-1 cells imply that JEV might play an important role in CNS
inflammation and diseases.
Background
Japanese encephalitis virus (JEV) is a single-stranded,
positive-sense RNA virus belonging to the family flavi-
viridae. JEV is transmitted between animals and human
host by culex mosquitoes [1,2]. After the bite of an
infected mosquito, JEV amplifies peripherally producing
transient viremia before entering into the central ner-
vous system (CNS) [2]. The principal target cells for
JEV are in the CNS, and include neurons and astrocytes
[3]. Several lines of evidence suggest that JEV frequently
causes severe encephalitic illness, and is one of the most
important endemic encephalitides in the world, espe-
cially in Eastern and Southeastern Asia, clinically mani-
festing with fever, headache, vomiting, signs of
meningeal irritation and altered consciousness leading
to high mortality [1-3]. In CNS injuries and in diseases
such as encephalitis, matrix metalloproteinases (MMPs)
play an important role in the regulation of pathological
processes in the CNS [4-6].
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which process a large number of pericellular substrates.
The distinctive characteris t i c so ft h i ss u b g r o u po f
matrixins is their dependence on zinc ion at the active
site, the presence of a cysteine switch motif in the pro-
peptide, and a zinc-binding domain in the catalytic
domain [7]. In the CNS, MMPs are implicated in var-
ious processes involved in development, such as migra-
tion of precursor cells, axonal outgrowth, and
myelinogenesis. In accordance with the role of MMPs in
degrading the extracellular microenvironment, gelati-
nases might regulate the migration of different neural
cell types to their final destinations [7]. In addition,
MMPs also regulate CNS pathological processes that
may contribute to the progression of CNS injuries and
diseases, such as demyelination, blood-brain barrier
(BBB) and blood-nerve barrier opening, invasion of
neural tissue by blood-derived immune cells, modulation
of neuroinflammation, and direct neurotoxicity [6,8,9].
within the MMP family, gelatinases, MMP-2 and MMP-
9 mediate lesion development in response to brain
injury. MMP-2 (gelatinase A; 72 kDa) is constitutively
expressed by several cell types, including brain cells. In
contrast, basal levels of MMP-9 (gelatinase B; 92 kDa)
are usually low in normal physiological conditions and
are increased by various stimuli, such as TNF-a and IL-
1b [6,10-12].
Up-regulation of MMP-9 by viral infection has been
shown to trigger tissue injury in various organs. For
instance, the gp120 protein of the human immunodefi-
ciency virus (HIV) disrupts the BBB by increasing
MMP-9 and reducing vascular tight junction proteins
via mechanisms involving ROS generation and oxidant
injury [13,14]. Moreover, our previous study demon-
strated that JEV induces expression of MMP-9 that
causes brain damage in mice, and that this expression is
reduced by pretreatment with MMP-9 inhibitor in vivo
[15].
Expression of MMP-9 can be induced by extracellular
stimuli at the transcriptional and translational levels
[16,17]. Many reports have shown that the promoter of
MMP-9 possesses a series of functional activator/enhan-
cer element-binding sites, including NF-B and activator
protein-1 (AP-1) [5,9]. Our previous study reported that
JEV-induced MMP-9 expression is mediated through
NF-B[ 1 5 ] ,b u tt h er o l eo fA P - 1i nM M P - 9g e n e
expression induced by JEV is still unknown. AP-1 is a
dimeric transcription factor comprising proteins from
several families whose common denominator is posses-
sion of basic leucine zipper (bZIP) domains that are
essential for dimerization and DNA binding. Moreover,
various stimuli lead to the expression and/or activation
of c-Fos and c-Jun products which heterodimerize and
bind to AP-1 sites within MMP-9 gene promoters [18].
Recent studies have further demonstrated that several
external stimuli can up-regulate MMP-9 expression via
AP-1 in different cell types [19,20]. Therefore, in this
study, we sought to determine whether expression of
MMP-9 by JEV infection is mediated through AP-1.
Several factors can activate signaling transductions
that enhance AP-1 activity [21]. For example, in NIH
3T3 mouse fibroblasts, platelet-derived growth factor
(PDGF)-stimulated JNK1/2-dependent activation of c-
Jun and p42/p44 MAPK-dependent activation of c-Fos
leads to the expression of c-myc that regulates normal
and aberrant cell growth [22,23]. In addition, iron
increases MMP-9 expression by increasing AP-1 binding
via p42/p44 MAPK and Akt activation in head and neck
squamous carcinoma cells [24]. Moreover, several stu-
dies have shown that stimulation of the signaling path-
ways by viral infection, such as hepatitis B virus (HBV),
influenza virus, and Kaposi’s sarcoma-associated herpes-
virus leads to activation of AP-1 [25,26]. Nonetheless,
the mechanisms underlying JEV-stimulated activation of
signaling pathways associated with AP-1 in astrocytes
are not completely elucidated.
A recent study from our laboratory shows that JEV-
induced MMP-9 expression is mediated through reactive
oxygen species (ROS)/MAPKs-dependent NF-B activa-
tion in rat brain astrocytes (RBA-1 cells) [15]. In the pre-
sent study, the major signaling pathways linked to AP-1
activation and MMP-9 expression by JEV were investi-
gated in RBA-1 cells. Our results demonstrate that JEV-
induced MMP-9 expression is mediated through ROS/c-
Src/PDGFR/PI3K/Akt/MAPKs-dependent activation of
AP-1 signaling pathway in RBA-1 cells.
Methods
Materials
Anti-PDGFR, anti-c-Src, anti-Akt, anti-c-Fos, and anti-
b-actin antibodies were obtained from Santa Cruz
(Santa Cruz, CA). Anti-phospho-PDGFR, anti-phospho-
c-Src, anti-phospho-p42/p44 MAPK, anti-phospho-p38
MAPK, anti-phospho-JNK1/2, and anti-phospho-Akt
antibodies were from Cell Signaling (Danver, MA).
Anti-GAPDH antibody was from Biogenesis (Bourne-
mouth, UK). AG1296, PP1, LY294002, U0126,
SB203580, SP600125, tanshinone, and diphenyleneiodo-
nium chloride (DPI) were from Biomol (Plymouth Meet-
ing, PA). Apocynin (APO) was purchased from
ChromaDex (Santa Ana, CA). N-acetyl-L-cysteine
(NAC), gelatin, enzymes, and other chemicals from
Sigma (St. Louis, MO).
Preparation of viruses
The T1P1 strain of JEV was propagated in C6/36 cells
as previously described [15]. The titer of JEV was deter-
mined by a plaque assay.
Yang et al. Journal of Neuroinflammation 2012, 9:12
http://www.jneuroinflammation.com/content/9/1/12
Page 2 of 15Rat brain astrocyte-1 culture
RBA-1 cells were used throughout this study. This cell
line originated from a primary astrocyte culture of neo-
natal rat cerebrum and naturally developed through suc-
cessive cell passages. RBA-1 cells were stained for glial
fibrillary acid protein (GFAP) as an astrocyte-specific
marker and used within 40 passages, which show nor-
mal cellular morphological characteristics and have
steady growth and proliferation in the monolayer system
[16].
MMP gelatin zymography
After JEV treatment, culture medium was collected and
mixed with equal amounts of non-reduced sample buf-
fer and electrophoresed on 10% SDS-polyacrylamide
gels containing 1 mg/ml gelatin as a protease substrate.
Following electrophoresis, gels were placed in 2.7% Tri-
ton X-100 for 30 min to remove SDS, and then incu-
bated for 24 h at 37°C in developing buffer (50 mM Tris
base, 40 mM HCl, 200 mM NaCl, 5 mM CaCl2,a n d
0.2% Briji 35; Novex) on a rotary shaker. After incuba-
tion, gels were stained in 30% methanol, 10% acetic
acid, and 0.5% w/v Coomassie brilliant blue for 10 min
followed by destaining. Mixed human MMP-2 and
MMP-9 standards (Chemicon) were used as positive
controls. Gelatinolytic activity was manifested as hori-
zontal white bands on a blue background. Since cleaved
MMPs are not reliably detected, only proform zymogens
were quantified.
Transient transfection with siRNAs
The small interfering RNA (siRNA) duplexes corre-
sponding to rat c-Fos (RSS320774, RSS320772, and
RSS359279), c-Jun (RSS340670, RSS351339, and
RSS340668), PDGFR (RSS351968, RSS351967, and
RSS351966), Akt (RSS301983, RSS301984, and
RSS301985), and scrambled siRNA were from Invitrogen
(Carlsbad, CA). Transient transfection of siRNAs (100
nM) was performed using a Lipofetamine™ RNAiMAX
reagent according to the manufacturer’s instructions.
Total RNA extraction and RT-PCR analysis
Total RNA was isolated from RBA-1 cells (10-cm cul-
ture dishes) incubated with JEV for the indicated time
intervals, using TRIzol according to the protocol of the
manufacturer. RNA concentration was spectrophotome-
trically determined at 260 nm. First strand cDNA synth-
esis was performed with 2 mg of total RNA using
random hexamers as primers in a final volume of 20 ml
(5 mg/ml random hexamers, 1 mM dNTPs, 2 units/ml
RNasin, and 10 units/ml Moloney murine leukemia
virus reverse transcriptase). The reaction was carried
out at 37°C for 60 min. cDNAs encoding b-actin, MMP-
9, c-Jun, and c-Fos were amplified from 3-5 ml of the
cDNA reaction mixture using specific gene primers. Oli-
gonucleotide primers for MMP-9, b-actin, c-Jun, and c-
Fos were as follow:
MMP-9
5’-AGTTTGGTGTCGCGGAGCAC-3’ (sense)
5’-TACATGAGCGCTTCCGGCAC-3’ (antisense)
b-actin
5’-TGACGGGGTCACCCACACTGTGCCCATCTA-3’
(sense)
5’-CTAGAAGCATTTGCGGTGGACGATG-3’
(antisense)
c-Jun
5’-ATGACTGCAAAGATGGAAACG-3’ (sense)
5’-TATTCTGGCTATGCAGTTCAG-3’ (anti-sense)
c-Fos
5’-ACTGCGAGAACCAAGCTACTGCTG-3’ (sense)
5’-GTACGTCCATTGACATGTTGCTCAG-3’ (anti-
sense)
Western blot analysis
Growth-arrested RBA-1 cells were incubated with JEV at
37°C for various time intervals. The cells were washed
with ice-cold PBS, scraped, and collected by centrifuga-
tion at 45000 × g for 1 h at 4°C to yield the whole cell
extract, as previously described [16]. Samples were dena-
tured, subjected to SDS-PAGE using a 10% (w/v) run-
ning gel, and transferred to nitrocellulose membrane.
Membranes were incubated overnight using an anti-
phospho-PDGFR, anti-phospho-c-Src, anti-phospho-Akt,
anti-phospho-p42/p44 MAPK, anti-phospho-JNK1/2,
anti-phospho-p38 MAPK, or anti-GAPDH antibody.
Membranes were then washed with TTBS four times for
5 min each, incubated with 1:2000 dilution of anti-rabbit
or anti-mouse horseradish peroxidase antibody for 1 h
at room temperature. Immunoreactive bands were
detected using ECL reagents.
Co-immunoprecipitation assay
Cell lysates containing 1 mg of proteins were incubated
with 2 μg of anti-c-Src antibody at 4°C for 1 h, and then
10 μl of 50% protein A-agarose beads was added and
mixed at 4°C for 16 h. The immunoprecipitates were
collected and washed thrice with lysis buffer without
Triton X-100; 5× Laemmli buffer was added, and then
subjected to electrophoresis on 10% SDS-PAGE. Wes-
tern blot analysis was performed using an antibody
against either anti-c-Src or anti-phospho-PDGFR
antibody.
Rat MMP-9 promoter cloning, transient transfection, and
promoter activity assay
The upstream region (-1280 to +19) of the rat MMP-9
promoter was cloned to the pGL3-basic vector contain-
ing the luciferase reporter system. Briefly, a 1.3-kb
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gene was amplified by PCR using specific primers for
the rat MMP-9 gene (accession no. U36476): 5’-
ccccggtaccGAAGGCGAAATGCTTTGCCC (forward/
Kpn1) and 5’-ccccctcgaGGGTGAGAACC-
GAAGCTTCTG (reverse/Xho1). The pGL3-Basic vec-
tor, containing a polyadenylation signal upstream from
the luciferase gene, was used to construct the expression
vectors by subcloning PCR-amplified DNA of the MMP-
9 promoter into the Kpn1/Xho1 site of this vector. The
PCR products (pGL3-MMP-9WT) were confirmed by
their size, as determined by electrophoresis and by DNA
sequencing. Additionally, the introduction of a mis-
matched primer mutation into the AP-1 to generate
pGL3-MMP-9 distal ΔAP-1/wtEts was performed, using
the following (forward) primer: distal ΔAP-1/wtEts: 5’-
GCAGGAGAGGAAGCTGAGTTGAAGACA-3’.A l l
plasmids were prepared by using QIAGEN plasmid
DNA preparation kits. The MMP-9 promoter reporter
construct was transfected into RBA-1 cells using the
Lipofectamine reagent according to the instructions of
the manufacturer. To assess promoter activity, cells
were collected and disrupted by sonication in lysis buf-
fer (25 mM Tris-phosphate, pH 7.8, 2 mM EDTA, 1%
Triton X-100, and 10% glycerol). After centrifugation,
aliquots of the supernatants were tested for luciferase
activity using the luciferase assay system. Firefly lucifer-
ase activities were standardized to those of b-galactosi-
dase activity.
Chromatin immunoprecipitation assay
To detect the in vivo association of nuclear proteins
with rat MMP-9 promoter, chromatin immunoprecipi-
tation (ChIP) analysis was conducted as previously
described [27]. Briefly, RBA-1 cells were cross-linked
with 1% formaldehyde for 10 min at 37°C and washed
thrice with ice-cold PBS containing 1 mM phenyl-
methylsulfonyl fluoride (PMSF) and 1% aprotinin.
Soluble chromatin was prepared using a ChIP assay kit
(Upstate) according to the manufacturer’s recommen-
dations and immunoprecipitated without (control) or
with anti-c-Fos or anti-c-Jun antibody and normal goat
immunoglobulin G (IgG). Following washes and elu-
tion, precipitates were heated overnight at 65°C to
reverse cross-linking of DNA and protein. DNA frag-
ments were purified by phenol-chloroform extraction
and ethanol precipitation. The purified DNA was sub-
jected to PCR amplification using the primers specific
for the region (-597 to -318) containing the distal AP-
1 binding site (-503 to -497) present in the MMP-9
promoter region, sense primer: 5’-AGAGCCTGCTCC-
CAGAGGGC-3’; antisense primer: 5’-GCCAAGT-
CAGGCAGGACCCC-3’. PCR fragments were analyzed
on 2% agarose in 1× TAE gel containing ethidium bro-
mide and the size (279 bp) was compared to a molecu-
lar weight marker.
Statistical analysis of data
Concentration-effect curves were fitted and EC50 values
were estimated using a GraphPad Prism Program
(GraphPad, San Diego, CA, USA). Data were expressed
as mean ∀ S.E.M. and analyzed by one-way ANOVA fol-
lowed with Tukey’s post-hoc test. P < 0.05 was consid-
ered significant.
Results
AP-1 is involved in JEV-induced proMMP-9 expression
The promoter region of MMP-9 possesses an AP-1
binding site that is regulated by several external sti-
muli in different cell types [18-20]. Therefore, we first
determined whether JEV-induced MMP-9 expression
was mediated through AP-1 in RBA-1 cells. As shown
by the gelatin zymographic experiments in Figure 1A,
pretreatment with an inhibitor of AP-1 (tanshinone)
attenuated JEV-induced MMP-9 expression in a con-
centration-dependent manner. Within the AP-1 sub-
family, c-Jun is an important transcriptional activator
and c-Fos transactivates MMPs by binding directly to
promoter AP-1 motifs [21,28]. Thus, we used the
siRNA transfection technique to verify whether c-Jun
and c-Fos were required for MMP-9 expression
induced by JEV. As shown in Figure 1B, transfection
with either c-Jun or c-Fos siRNA down-regulated
total c-Jun or c-Fos protein expression and signifi-
cantly reduced JEV-induced MMP-9 expression in
RBA cells.
Next, we found that the action of AP-1 in regulating
MMP-9 expression occurred at the transcriptional level
in RBA-1 cells, since pretreatment with tanshinone sig-
nificantly attenuated JEV-induced MMP-9 mRNA accu-
mulation (Figure 1C). To ensure the transcriptional
regulation of MMP-9 gene in this context, RBA-1 cells
were transfected with a luciferase reporter vector con-
taining an exogenous MMP-9 promoter, and the cells
were then stimulated with JEV for 6 h. As shown in Fig-
ure 1D, JEV infection stimulated MMP-9 promoter
activity, which was attenuated by pretreatment with tan-
shinone in RBA cells. To further confirm the role of
AP-1 in JEV-mediated MMP-9 promoter induction, a
point-mutated AP-1 MMP-9 promoter construct was
used. As shown in Figure 1E, JEV-stimulated MMP-9
promoter activity was prominently lost in RBA-1 cells
transfected with the point-mutated AP-1 MMP-9 pro-
moter. These results suggest that AP-1 (c-Jun and c-
Fos) is required for JEV-induced MMP-9 expression in
RBA-1 cells.
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The regulation of AP-1 activity depends on changes in
c-Jun and c-Fos gene transcription and mRNA accumu-
lation [21]. In addition, we demonstrated that transfec-
tion of c-Jun or c-Fos siRNA diminished JEV-induced
MMP-9 expression (Figure 1B). Therefore, we explored
the up-regulation of AP-1 by JEV with respect to c-Jun
and c-Fos mRNA expression, using RT-PCR. The results
show that stimulation of RBA-1 cells with JEV induces
c-Jun and c-Fos gene expression in a time-dependent
manner. The expression of c-Jun and c-Fos by JEV
infection reached a peak within 20 min and declined to
basal levels within 60 min (Figure 2A). In addition, JEV
also induced c-Jun and c-Fos protein expression in a
time-dependent manner (Figure 2B). To further
Figure 1 Involvement of AP-1 in MMP-9 expression with JEV infection of RBA cells. (A, B) Cells were pretreated with tanshinone for 1 h or
transfected with siRNA of scrambled (scrb), c-Jun, or c-Fos, and then infected with JEV for 16 h. The conditioned media were used to determine
MMP-9 expression by gelatin zymography. Cell lysates were analyzed by western blot using an anti-c-Jun, anti-c-Fos, or anti-GAPDH antibody. (C)
Cells were pretreated with tanshinone for 1 h, and then incubated with JEV for 6 h. RNA samples were analyzed by RT-PCR to assess the levels
of MMP-9 mRNA expression. (D, E) Cells were transiently transfected with MMP-9-luc reporter gene, pretreated with tanshinone (10 μM) for 1 h,
and then incubated with JEV for 6 h. In addition, cells were transfected with wild-type MMP-9 promoter and AP-1-mutated MMP-9 promoter,
and then incubated with JEV (moi = 1) for 6 h. MMP-9 promoter activity was determined in the cell lysates. Data are expressed as mean ± S.E.M.
for five independent experiments. *P < 0.05;
#P < 0.01, as compared with the cells exposed to JEV alone (A, D).
#P < 0.01, as compared with cells
transfected with wild-type MMP-9 promoter stimulated by JEV (E).
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lated by JEV infection, RBA-1 cells were transfected
with an AP-1-luciferase reporter gene. JEV infection
enhanced AP-1 transcriptional activity in a time-
dependent manner with a maximal response within 30
min (Figure 2C). These results indicate that JEV infec-
tion induces AP-1 activation through c-Jun and c-Fos in
RBA-1 cells. On the other hand, we used a ChIP assay
Figure 2 EV71 infection induces activation of AP-1 via c-Src, PDGFR, and PI3K/Akt. Cells were incubated with JEV (moi = 1) for the
indicated time intervals. (A) mRNA levels for c-Jun and c-Fos were determined by RT-PCR. (B) Protein levels of c-Jun and c-Fos were determined
by western blotting. (C) Cells were transfected with an AP-1 promoter luciferase construct or control vector (pGL3-Luc) together with a b-
galactosidase plasmid, and then incubated with JEV (moi = 1) for the indicated time intervals. AP-1 promoter activity was normalized to that of
b-galactosidase activity. (D) Cells were incubated with JEV (moi = 1) for the indicated time intervals. c-Fos and c-Jun binding activities were
analyzed by chromatin immunoprecipitation (ChIP) assay. (E, F) Cells were pretreated with AG1296 (AG, 10 μM), PP1 (10 μM), or LY294002 (LY, 30
μM) for 1 h, and then incubated with JEV (moi = 1) for (E) 20 min or (F) 60 min. (E) mRNA expression for c-Jun and c-Fos were examined by RT-
PCR. (F) Protein levels of c-Jun and c-Fos were determined by western blotting. (G) Cells were transfected with an AP-1 promoter luciferase
construct or control vector (pGL3-Luc) together with a b-galactosidase plasmid, pretreated with AG1296 (AG, 10 μM), PP1 (10 μM), or LY294002
(LY, 30 μM) for 1 h, and then incubated with JEV (moi = 1) for 30 min. The AP-1 promoter activity was normalized to that of b-galactosidase
activity. Data are expressed as mean ± S.E.M. for five independent experiments.
#P < 0.01, as compared with the basal level (C). *P < 0.05, as
compared with cells exposed to JEV alone (G).
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AP-1 to MMP-9 promoter is involved in MMP-9 gene
expression. We designed a pair of primers for MMP-9
promoter (-597 to -318) region, containing an AP-1
binding site. Chromatin was immunoprecipitated using
an anti-c-Fos or anti-c-Jun antibody, and the MMP-9
promoter region (-597 to -318) was amplified by PCR.
As shown in Figure 2D, JEV stimulated in vivo binding
of c-Fos and c-Jun to the MMP-9 promoter in a time-
dependent manner with a maximal response within 60
min.
Previous studies have reported that AP-1 activation is
mediated through PDGFR signaling pathways [22,23]. In
addition, our previous study reported that enterovirus
71 (EV71) induces AP-1 activation via a c-Src/PDGFR/
PI3K/Akt cascade in RBA-1 cells [29]. Therefore, to
further determine whether c-Jun/c-Fos gene expression
and AP-1 transcriptional activity are mediated through
activation of c-Src, PDGFR, and PI3K/Akt by JEV infec-
tion, inhibitors of PDGFR (AG1296), c-Src (PP1), or
PI3K/Akt (LY294002) were used to assess transcriptional
activity. These results show that JEV-enhanced c-Jun/c-
Fos protein levels, mRNA expression, and AP-1 tran-
scriptional activity were significantly attenuated by pre-
treatment with AG1296, PP1, or LY294002 (Figures 2E-
G). These results suggest that JEV-stimulated AP-1 acti-
vation is mediated through c-Src, PDGFR, and PI3K/Akt
in RBA-1 cells.
JEV-induced proMMP-9 expression is mediated via a c-
Src/PDGFR signaling
To determine if PDGFR activation occurs upon expo-
sure of JEV, phosphorylated PDGFR was determined by
western blot using specific antibody to the active form
of PDGFR. As shown in Figure 3A, JEV infection stimu-
lated PDGFR phosphorylation in a time-dependent man-
ner, which was inhibited by pretreatment with AG1296
(an inhibitor of PDGFR). Previous studies have reported
that growth factor receptors are activated through trans-
activation of activated c-Src by various stimuli [30].
Therefore, we determined whether c-Src mediates trans-
activation of PDGFR in response to JEV infection. As
depicted in Figure 3A, JEV-stimulated PDGFR phop-
sphorylation was reduced by pretreatment with PP1 (an
inhibitor of c-Src). Moreover, a co-immunoprecipitation
study revealed that JEV infection-stimulated c-Src
directly associated with PDGFR in a time-dependent
manner with a maximal response within 3-5 min (Figure
3B). Further, pretreatment with PP1, but not AG 1296,
diminished JEV infection-induced c-Src phosphorylation
(Figure 3C). These results indicate that c-Src is an
upstream component of PDGFR in JEV-mediated
responses in RBA-1 cells.
We further determined whether JEV-induced MMP-9
expression is mediated through c-Src/PDGFR in RBA-1
cells. As shown in Figures 3D and 3E, pretreatment with
either AG1296 or PP1 attenuated JEV-induced MMP-9
expression in a concentration-dependent manner.
Further, transfection of PDGFR siRNA attenuated JEV-
induced MMP-9 expression in RBA-1 cells (Figure 3D).
All these results together suggest that JEV-induced
MMP-9 expression is mediated through the c-Src/
PDGFR/AP-1 cascade in RBA-1 cells.
Involvement of PI3K/Akt pathway in JEV-induced
proMMP-9 expression
Next, we investigated whether JEV-induced MMP-9
expression is mediated through PI3K/Akt signaling in
RBA-1 cells. First, we verified that Akt is activated upon
exposure to JEV, using an antibody specific for the
phosphorylated, active form of Akt, by western blotting.
As shown in Figure 4A, JEV infection-increased Akt
phosphorylation was observed in a time-dependent
manner with a maximal response within 5 min, which
was inhibited by pretreatment with LY294002 during
the period of observation (Figure 4A). In addition, it is
known that PI3K/Akt is activated following stimulation
of receptor tyrosine kinases by different stimuli in var-
ious cell types [30-33]. Therefore, we used AG1296 and
PP1 to confirm this possibility in this cascade. As illu-
strated in Figure 4A, JEV-stimulated Akt phosphoryla-
tion was attenuated by pretreatment with either
AG1296 or PP1, indicating that JEV infection-stimulated
PI3K/Akt activation was mediated through c-Src/
PDGFR in RBA-1 cells.
We further determined whether JEV-induced MMP-9
expression is mediated through PI3K/Akt in RBA-1
cells. As shown in Figures 4B and 4C, pretreatment with
LY294002 or transfection with Akt siRNA attenuated
JEV-induced MMP-9 expression in RBA-1 cells. Taken
together, these results suggest that JEV-induced MMP-9
expression is mediated through c-Src/PDGFR/PI3K/Akt/
AP-1 signaling in RBA-1 cells.
c-Src, PDGFR, and PI3K/Akt are required for JEV-induced
MMP-9 mRNA expression
We further examined whether c-Src, PDGFR, and Akt
are involved in regulation of MMP-9 expression at the
transcriptional level in RBA-1 cells. As shown in Figures
5A and 5B, pretreatment of RBA cells with AG1296,
LY294002, or PP1 significantly attenuated JEV-induced
MMP-9 mRNA accumulation and MMP-9 promoter
activity. These results further confirm that in JEV-
infected RBA-1, up-regulation of MMP-9 gene through
activation of c-Src, PDGFR, and Akt mainly occurrs at
the transcriptional level.
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Page 7 of 15Figure 3 JEV infection induces MMP-9 expression through c-Src/PDGFR in RBA-1 cells. (A) Cells were pretreated with AG1296 (10 μM) or
PP1 (10 μM) for 1 h, and then infected with JEV (moi = 1) for the indicated time intervals. The cell lysates were analyzed by western blot using
an anti-phospho-PDGFR or anti-GAPDH antibody. (B, C) Cells were pretreated without or with AG1296 (AG, 10 μM) or PP1 (10 μM) for 1 h, and
then incubated with JEV (moi = 1) for the indicated time intervals (B) or 5 min (C). Cell lysates were subjected to immunoprecipitation using an
anti-c-Src antibody. The immunoprecipitates were analyzed by western blot using an anti-c-Src, anti-phospho-c-Src, or anti-phospho-PDGFR
antibody. (D, E) Cells were pretreated with AG1296 or PP1 for 1 h or transfected with PDGFR siRNA, followed by incubation with JEV for 16 h.
Cell lysates were analyzed by western blot using an anti-PDGFR or anti-GAPDH antibody. The conditioned media were used to determine MMP-
9 expression by gelatin zymography. Data are expressed as mean ± S.E.M. for five independent experiments.
#P < 0.01, as compared with cells
exposed to JEV alone [D (left panel), E].
#P < 0.01, as compared with cells transfected with scrambled siRNA exposed to JEV (D, right panel).
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Page 8 of 15Figure 4 Involvement of PI3K/Akt in JEV-induced MMP-9 expression in RBA-1 cells. (A) Cells were pretreated with LY294002 (30 μM),
AG1296 (10 μM), or PP1 (10 μM) for 1 h, and then infected with JEV (moi = 1) for the indicated time intervals. Cell lysates were analyzed by
western blot using an anti-phospho-Akt or anti-GAPDH antibody. (B, C) Cells were pretreated with LY294002 for 1 h or transfected with Akt
siRNA, followed by incubation with JEV for 16 h. The cell lysates were analyzed by western blot using an anti-Akt or anti-GAPDH antibody. The
conditioned media were used to determine MMP-9 expression by gelatin zymography. Data are expressed as mean ± S.E.M. for five independent
experiments.
#P < 0.01, as compared with the cells exposed to JEV alone.
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Page 9 of 15JEV-induced AP-1 expression is mediated via MAPKs
Our previous study has shown that the mechanism
whereby JEV infection leads to the expression of MMP-
9i sm e d i a t e dv i ap 4 2 / p 4 4M A P K ,p 3 8M A P K ,a n d
JNK1/2 in RBA-1 cells [15]. In addition, previous studies
have reported that AP-1 activation is also mediated
through MAPKs signaling stimulated by various factors
in various cell types [21,28]. Thus, we investigated
whether activation of AP-1 by JEV infection is mediated
through MAPKs signaling in RBA-1 cells. AP-1 activa-
tion was assessed following JEV infection in the pre-
sence of inhibitor for p42/p44 MAPK (U0126), p38
MAPK (SB203580), or JNK1/2 (SP600125). These data
show that JEV-induced c-Jun/c-Fos gene expression and
AP-1 transcriptional activity were significantly blocked
by pretreatment with U0126, SB203580, and SP600125
(Figures 6A and 6B). These results suggest that JEV-
induced AP-1 activation is MAPKs dependent in RBA-1
cells.
The receptors for epidermal growth factor (EGF),
PDGF, brain-derived neurotrophic factor (BDNF), and
nerve growth factor (NGF) regulate many signaling
components involved in MAPKs cascades [34]. Thus, we
determined whether activation of MAPKs by JEV infec-
tion in RBA-1 cells is mediated through c-Src/PDGFR/
PI3K/Akt pathway. Phosphorylation of p42/p44 MAPK,
p38 MAPK, and JNK1/2 by JEV infection was decreased
by pretreatment with AG1296, PP1, and LY294002 in
RBA-1 cells (Figures 6C-E). Taken together, these
results suggest that c-Src/PDGFR/PI3K/Akt/MAPKs/
AP-1 signaling is involved in MMP-9 expression
induced by JEV infection in RBA-1 cells.
c-Src/PDGFR/PI3K/Akt cascade activation is dependent on
ROS by JEV infection
Our previous study has shown that JEV infection
induces ROS generation through NADPH oxidase,
which in turn activates MAPKs pathway in RBA-1 cells
[15]. Moreover, several studies indicate that ROS pro-
duction leads to c-Src activation, which strongly
increases kinase activity [35-37]. Therefore, to investi-
gate whether activation of c-Src by JEV infection is
mediated through ROS, inhibitors of NADPH oxidase
(APO and DPI) and a ROS scavenger (NAC) were used.
As shown in Figure 7A, pretreatment with APO, DPI, or
NAC attenuated JEV-stimulated PDGFR and c-Src phos-
phorylation in the complex immunoprecipitated by
using an anti-c-Src antibody, indicating that JEV-stimu-
lated c-Src/PDGFR activation is mediated through
NADPH oxidase/ROS generation in RBA-1 cells. Next,
we determined whether NADPH oxidase/ROS modu-
lates PDGFR and PI3K/Akt signaling pathway by JEV
infection in RBA-1 cells. As shown in Figures 7B and
7C, pretreatment with APO, DPI, or NAC significantly
attenuated JEV-stimulated PDGFR and Akt phosphory-
lation. Taken together, these results indicate that JEV-
stimulated phosphorylation of c-Src/PDGFR/PI3K/Akt
pathway is mediated through NADPH oxidase/ROS in
RBA-1 cells.
Discussion
Neurotropic viruses can cause massive neuronal dys-
function and destruction that leads to neurological dis-
eases [1]. Based on neural cell composition and the
barrier between the peripheral tissues and CNS, astro-
cytes might play a role in the transmission of virus from
peripheral blood flow into the CNS. Recent studies have
demonstrated a relationship between elevated levels of
MMP-9 and severity of several pathological states in the
CNS [5,6]. MMP-9 has been shown to degrade compo-
nents of the basal lamina, leading to disruption of the
BBB, and to contribute to neuroinflammatory responses
in many neurological diseases [38]. Several lines of evi-
dence have shown that reduction of MMP activity by
pharmacological inhibitors or gene knock-out strategies
Figure 5 Involvement of c-Src/PDGFR/PI3K/Akt in MMP-9
mRNA expression induced by JEV in RBA-1 cells. (A) Cells were
pretreated with AG1296 (AG12, 10 μM), PP1 (10 μM), or LY294002
(LY, 30 μM) for 1 h, and then infected with JEV for 6 h. RNA
samples were analyzed by RT-PCR to determine levels of MMP-9
mRNA. (B) Cells were transiently transfected with an MMP-9-luc
reporter gene, pretreated with AG1296 (AG12, 10 μM), PP1 (10 μM),
or LY294002 (LY, 30 μM) for 1 h, and then infected with JEV for 6 h.
The promoter activity of MMP-9 was measured. Data are expressed
as mean ± S.E.M. for five independent experiments.
#P < 0.01, as
compared with the cells exposed to JEV alone.
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Page 10 of 15protects the brain from BBB disruption, cell death, and
advanced neuroinflammation [5,39]. Previous studies
have indicated that several signaling cascades are
involved in MMP-9 expression by virus infection
[13,14]. We have previously demonstrated that JEV
infection induces MMP-9 expression via NF-B in RBA-
1 cells [15]. Moreover, AP-1 is also known to play an
important role in MMP-9 expression in various cell
types [18]. However, little is known about the molecular
mechanisms of JEV-induced AP-1 activation leading to
MMP-9 expression in RBA-1 cells. In this study, the
mechanisms underlying JEV-induced MMP-9 expression
were investigated using selective pharmacological inhibi-
tors or transfection with siRNAs. The requirement of
transcription factors for the regulation of JEV-induced
MMP-9 gene expression was determined by reporter
gene assays. These results demonstrate that JEV induces
MMP-9 expression via a ROS, c-Src, PDGFR, PI3K/Akt,
p42/p44 MAPK, p38 MAPK, and JNK1/2-dependent
pathway following activation of transcription factor AP-
1 (c-Jun and c-Fos) in RBA-1 cells.
Previous studies have reported that the promoter of
MMP-9 possesses a series of functional activator ele-
ment-binding sites, including NF-B and AP-1 [6,9]. In
addition, AP-1 activity is enhanced by various factors
including growth factors, cytokines, physical and chemi-
cal stresses, and bacterial and viral infections [21,28].
However, AP-1 participation in MMP-9 expression is
poorly understood in JEV-infected RBA-1 cells. First, we
therefore determined the requirement for AP-1 in JEV-
induced MMP-9 expression. Our results reveal that JEV
infection stimulates expression of MMP-9, which was
significantly inhibited by pretreatment with tanshinone
and transfection with c-Jun siRNA and c-Fos siRNA. In
addition, JEV-induced MMP-9 mRNA expression and
promoter activity were attenuated by pretreatment with
tanshinone or transfection with a point-mutated AP-1
MMP-9 promoter, indicating that AP-1 participates in
MMP-9 expression by JEV infection in RBA-1 cells.
Moreover, we demonstrated that JEV-induced AP-1 acti-
vation occurs through changes in c-Jun and c-Fos gene
transcription and mRNA turnover. These results are
Figure 6 JEV infection activates AP-1 via c-Src/PDGFR/PI3K/Akt/MAPKs pathway. (A) Cells were pretreated with U0126 (U0, 1 μM),
SB203580 (SB, 1 μM), or SP600125 (SP, 1 μM) for 1 h, followed by stimulation with JEV for 20 min. The isolated RNA samples were analyzed by
RT-PCR, using the primers specific for c-Fos, c-Jun, and b-actin. (B) Cells were transfected with an AP-1 promoter luciferase construct together
with a b-galactosidase plasmid, pretreated with U0126 (U0, 1 μM), SB203580 (SB, 1 μM), or SP600125 (SP, 1 μM) for 1 h, and then incubated with
JEV for 30 min. AP-1 promoter activity was normalized to that of b-galactosidase activity. (C-E) Cells were pretreated with AG1296 (AG, 10 μM),
PP1 (10 μM), or LY294002 (LY, 30 μM) for 1 h, and then infected with JEV (moi = 1) for (C) 5, (D) 10, or (E) 30 min. The cell lysates were analyzed
by western blot using an anti-phospho-p42/p44 MAPK, anti-phospho-p38 MAPK, anti-phospho-JNK1/2, or anti-GAPDH antibody. Data are
expressed as mean ± S.E.M. for five independent experiments.
#P < 0.01, as compared with the cells exposed to JEV alone.
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Page 11 of 15Figure 7 JEV-induced c-Src/PDGFR/PI3K/Akt is mediated via ROS in RBA-1 cells. (A) Cells were pretreated with APO (100 μM), DPI (10 μM),
or NAC (10 mM) for 1 h, and then stimulated with JEV for 5 min. The cell lysates were subjected to immunoprecipitation using an anti-c-Src
antibody. The immunoprecipitates were analyzed by western blot analysis using an anti-c-Src, anti-phospho-c-Src, or anti-phospho-PDGFR
antibody. (B, C) Cells were pretreated with APO (100 μM), DPI (10 μM), or NAC (10 mM) for 1 h, and then incubated with JEV for 30 min. The cell
lysates were analyzed by western blot using an anti-phospho-PDGFR, anti-phospho-Akt, or anti-GAPDH antibody. Data are expressed as mean ±
S.E.M. for five independent experiments. *P < 0.05;
#P < 0.01, as compared with the cells exposed to JEV alone.
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Page 12 of 15consistent with previous studies demonstrating that
enhanced expression of MMP-9 in Epstein-Barr virus
(EBV)-infected or HBV-infected cells is mediated
through activation of AP-1 transcriptional activity
[40,41].
Several factors enhance AP-1 activity through activa-
tion of many signaling pathways, such as PDGF-induced
activation of AP-1 through p42/p44 MAPK and JNK1/2
in NIH 3T3 mouse fibroblasts [22,23]. In addition, our
previous study reported that EV71 induces AP-1 activa-
tion via a c-Src/PDGFR/PI3K/Akt cascade in RBA-1
cells [29]. However, activation of c-Src, PDGFR, and
PI3K/Akt by JEV is poorly understood in RBA-1 cells.
Therefore, our results from this present study reveal
that JEV infection induces expression of c-Jun and c-
Fos, and that these expressions are significantly inhibited
by pretreatment with AG1296, PP1, or LY294002. In
accord with our recent findings of COX-2 expression
with EV71 infection in RBA-1 cells [29], these data sug-
gest that AP-1 activation by JEV infection is mediated
through a c-Src, PDGFR, and PI3K/Akt pathway.
Next, we investigated the roles of c-Src, PDGFR, and
PI3K/Akt in MMP-9 expression in RBA-1 cells. Our
results show that JEV infection stimulates phosphoryla-
tion of PDGFR, which is attenuated by pretreatment
with AG1296 and PP1. In addition, co-immunoprecipi-
tation assays were performed to ensure that protein
levels of p-PDGFR and p-c-Src time-dependently
increase in a c-Src-immunoprecipitated complex stimu-
lated by JEV infection, which was inhibited by pretreat-
ment with AG1296 or PP1. Moreover, several studies
have reported that Akt is activated following stimulation
of receptor tyrosine kinase by different stimuli [30-32].
In addition, in rat brain astrocyte cells or neural cells,
PI3K/Akt activation has been shown to be mediated
through PDGFR transactivation [42-45]. In this study,
pretreatment of RBA-1 cells with AG1296 or PP1 inhib-
ited JEV-stimulated Akt phosphorylation, indicating that
activation of PDGFR and c-Src are required for this
response. Apart from these, pretreatment with AG1296,
PP1, or LY294002; or transfection with siRNA of
PDGFR or Akt significantly inhibited JEV-induced
MMP-9 protein expression and mRNA accumulation.
These data indicate that PI3K/Akt activation is mediated
through c-Src-dependent transactivation of PDGFR,
which promotes AP-1 activation and eventually leads to
MMP-9 expression with JEV infection of RBA-1 cells.
This result is consistent with recent studies reporting
that MMP-9 expression induced by IL-1b is mediated
via activation of c-Src/PDGFR/PI3K/Akt in various cell
types [45,46].
Previous studies have shown that AP-1 activation is
also mediated through MAPKs signaling pathways by
various factors in various cell types [21]. In addition, our
previous study has shown that JEV infection-induced
MMP-9 expression is mediated via ROS-p42/p44 MAPK,
p38 MAPK, and JNK1/2 in RBA-1 cells [15]. Thus, we
also investigated the roles of MAPKs in JEV-induced AP-
1 activation. Our results reveal that JEV infection induces
expression of c-Jun and c-Fos, which are significantly
inhibited by pretreatment with U0126, SP600125, or
SB203580. These data indicate that JEV-induced AP-1
activation is dependent on MAPKs in RBA-1 cells. More-
over, the MAPKs signaling cascade can be activated by
growth factors such as PDGF [34]. Therefore, we exam-
ined whether MAPKs activation by JEV infection is
mediated through a c-Src/PDGFR/PI3K/Akt pathway. In
this study, pretreatment with AG1296, PP1, or LY294002
inhibited JEV-stimulated phosphorylation of p42/p44
MAPK, p38 MAPK, and JNK1/2, indicating that activa-
tion of c-Src/PDGFR/PI3K/Akt pathway by JEV infection
regulates MAPKs activation in RBA-1 cells. These results
s u g g e s tt h a te x p r e s s i o no fM M P - 9w i t hJ E Vi n f e c t i o ni s
mediated through a c-Src/PDGFR/PI3K/Akt/MAPKs
pathway, associated with activation of transcription factor
AP-1 in RBA-1 cells. Next, we investigated the role of
ROS in activation of a c-Src/PDGFR/PI3K/Akt pathway
by JEV infection in RBA-1 cells. Our data reveal that JEV
infection-stimulated phosphorylation of PDGFR, c-Src,
and Akt are attenuated by pretreatment with APO, DPI,
or NAC. These data suggest that ROS plays an important
role in JEV-stimulated activation of the c-Src/PDGFR/
PI3K/Akt pathway in RBA-1 cells. Although MMP-9
induction is mediated by various stimuli and signaling
pathways, such as ROS/ERK1/2, JNK1/2/NF-B, PKCd/
ERK1/2/Elk-1, and Ras/Raf/MEK/ER1/2/NF-B
[27,47,48], our results are the first to show a novel role
for a ROS-dependent c-Src/PDGFR/PI3K/Akt/MAPKs/
AP-1 signaling pathway in JEV-induced MMP-9 expres-
sion in RBA-1 cells. In the future, we will investigate the
detailed mechanisms underlying JEV-induced MMP-9
expression in RBA-1 cells.
Conclusion
In this study, we investigated alternative mechanisms
underlying JEV-induced expression of MMP-9 in RBA-1
cells. This study demonstrates that JEV induces MMP-9
expression, which is mediated through a ROS-dependent
c-Src/PDGFR/PI3K/Akt/MAPKs signaling pathway lead-
ing to immediate early gene AP-1 activation (c-Jun and
c-Fos expression) in these cells. Based on observations
from the literature and on our findings, Figure 8 depicts
a model for the molecular mechanisms underlying JEV-
induced MMP-9 expression in RBA-1 cells. These find-
ings of JEV-induced MMP-9 expression in brain astro-
cytes imply that JEV might play a crucial role in the
Yang et al. Journal of Neuroinflammation 2012, 9:12
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Page 13 of 15development of brain injuries and CNS diseases and
provide useful support for the development of effective
therapeutic targets in brain inflammation.
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